Lauren Yantorni

Lauren Yantorni

Auto-generated profile, based on publicly available information

Lauren Yantorni

Winship Cancer Institute of Emory University, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in The Oncologist
Verified
Journal Article
Open access
PDF file
JBJacqueline T. Brown
Jacqueline T. Brown
YLYuan Liu
Yuan Liu
JSJulie M. Shabto
Julie M. Shabto
DMDylan J. Martini
Dylan J. Martini
DRDeepak Ravindranathan
Deepak Ravindranathan
MBMehmet Bilen
Mehmet Bilen
Background: The modified Glasgow prognostic score (mGPS), a clinical tool that incorporates albumin and C-reactive protein, has proven useful in the prognostication of multiple cancers. Several immune checkpoint inhibitors (ICIs) have been approved for the treatment of metastatic urothelial cell carcinoma (mUC), but a prognostic biomarker is needed. We investigated the impact of mGPS on survival outcomes in patients with mUC receiving ICIs. Materials and Methods: We retrospectively reviewed patients with mUC treated with ICIs (programmed cell death protein 1 or programmed cell death ligand 1 inhibitors) at Winship Cancer Institute from 2015 to 2018. Overall survival (OS) and progression-free survival (PFS) were measured from the start date of ICI until death or clinical or radiographic progression, respectively. mGPS was defined as a summary score with one point given for C-reactive protein >10 mg/L and/or albumin <3.5 g/dL. Univariate (UVA) and multivariate (MVA) analyses were carried out using Cox proportional hazard model. These outcomes were also assessed by Kaplan-Meier analysis. Results: A total of 53 patients were included with a median follow-up 27.1 months. The median age was 70 years, with 84.9% male and 20.8% Black. Baseline mGPS was 0 in 43.4%, 1 in 28.3% and 2 in 28.3%. Increased mGPS at the time of ICI initiation was associated with poorer OS and PFS in UVA, MVA, and Kaplan-Meier analyses. Conclusion: The mGPS may be a useful prognostic tool in patients with mUC when treatment with ICI is under consideration. These results warrant a larger study for validation. Implications for Practice: The ideal prognostic tool for use in a busy clinical practice is easy-to-use, cost-effective, and capable of accurately predicting clinical outcomes. There is currently no universally accepted risk score in metastatic urothelial cell carcinoma (mUC), particularly in the immunotherapy era. The modified Glasgow prognostic score (mGPS) incorporates albumin and C-reactive protein and may reflect underlying chronic inflammation, a known risk factor for resistance to immune checkpoint inhibitors (ICIs). This study found that baseline mGPS is associated with survival outcomes in patients with mUC treated with ICIs and may help clinicians to prognosticate for their patients beginning immunotherapy.

1 March 2021 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
DRDeepak Ravindranathan
Deepak Ravindranathan
GRGreta Anne Russler
Greta Anne Russler
LYLauren Yantorni
Lauren Yantorni
LDLeylah M. Drusbosky
Leylah M. Drusbosky
MBMehmet Bilen
Mehmet Bilen
Pembrolizumab has been approved by the US Food and Drug Administration for the treatment of metastatic or unresectable solid tumors that are microsatellite instability-high (MSI-H) or mismatch repair deficient. Blood-based circulating tumor DNA (ctDNA) assays have been validated to identify tumors with MSI-H status without the need for tissue biopsy. We report 2 patients with metastatic castration-resistant prostate cancer (mCRPC) who had prior treatment with multiple lines of therapy and underwent ctDNA testing, which detected MSI-H status. Both patients were treated with pembrolizumab, resulting in an excellent clinical response measured with liquid biopsies before and after initiation of therapy, which demonstrated a significant reduction in somatic-variant allele frequency in addition to a decrease in prostate serum antigen levels.

12 November 2021 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
DMDylan J. Martini
Dylan J. Martini
SESean T. Evans
Sean T. Evans
YLYuan Liu
Yuan Liu
JSJulie M. Shabto
Julie M. Shabto
OUOgul E. Uner
Ogul E. Uner
MBMehmet Bilen
Mehmet Bilen